

22 April 2024

## Acute Myeloid Leukaemia

**1. Do you treat patients with acute myeloid leukaemia (AML) in your Trust?**

Yes

If yes, please proceed to Question 3, if no, please answer Question 2

**2. Where do patients diagnosed with AML in your Trust receive treatment?**

Answer: n/a

**3. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 2023 to March 2024?**

**Azacitidine monotherapy**

**Low dose cytarabine (LoDAC) monotherapy**

**Venetoclax + azacitidine**

**Venetoclax + LoDAC**

**Ivosidenib**

**Intensive chemotherapy-based regimen**

**Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)**

**Best supportive care**

**Other**

**Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants**

**Note: this should only include patients with AML who have started first-line treatment during the 6-month window**

Unfortunately we can only provide information on the number of patients who have received these medications, we cannot provide any information relating to those patients diagnosis as this information is not centrally held. An extensive trawl of patient notes would be required.

We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more

**22 April 2024**

persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period October 2023 to March 2024
Azacitidine monotherapy	
(LoDAC) monotherapy	
Venetoclax + azacitidine	
Venetoclax + LoDAC	
Ivosidenib	
Intensive chemotherapy-based regimen	
Best supportive care	
Other	